SS
KALV

Steve Schonfeld’s KalVista Pharmaceuticals KALV Stock Holding History

Steve Schonfeld’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-315,537
Closed -$6.35M – 2804
2026
Q1 		$6.35M Buy
315,537
+9,657
+3% +$156K 0.04% 424
2025
Q4 		$4.94M Sell
305,880
-140,492
-31% -$1.86M 0.02% 546
2025
Q3 		$5.44M Buy
446,372
+301,090
+207% +$4.16M 0.03% 556
2025
Q2 		$1.64M Sell
145,282
-436,464
-75% -$5.34M 0.01% 1083
2025
Q1 		$6.71M Buy
+581,746
New +$5.94M 0.04% 439
2024
Q2 		– Sell
-12,800
Closed -$152K – 2361
2024
Q1 		$152K Buy
+12,800
New +$171K ﹤0.01% 1808
2019
Q4 		– Sell
-40,600
Closed -$471K – 1386
2019
Q3 		$471K Sell
40,600
-65,800
-62% -$1.06M 0.01% 662
2019
Q2 		$2.36M Buy
106,400
+95,400
+867% +$2.24M 0.08% 260
2019
Q1 		$315K Buy
+11,000
New +$238K 0.01% 821

Other funds holding KALV

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Steve Schonfeld's KALV Position: Q2 2026 in Review

Steve Schonfeld sold out of KalVista Pharmaceuticals (KALV) in Q2 2026, closing a stake of 315,537 shares — an estimated $6.35M sold.

Steve Schonfeld first reported a position in KALV in Q1 2019 and held it in 9 quarters. The position peaked at $6.71M in Q1 2025. 1 fund tracked by Wall St. Rank holds KALV as of Q2 2026.

  • Steve Schonfeld reported no remaining KalVista Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Steve Schonfeld sold 315,537 KalVista Pharmaceuticals shares in Q2 2026, an estimated $6.35M.
  • Steve Schonfeld first reported a position in KalVista Pharmaceuticals in Q1 2019 and held it in 9 quarters.
  • Steve Schonfeld's KalVista Pharmaceuticals position peaked at $6.71M in Q1 2025.
  • 1 fund tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.